Literature DB >> 26765961

I148M variant of PNPLA3 increases the susceptibility to non-alcoholic fatty liver disease caused by obesity and metabolic disorders.

M-F Xia1,2, Y Ling1,2, H Bian1,2, H-D Lin1,2, H-M Yan1,2, X-X Chang1,2, X-M Li1, H Ma3, D Wang1, L-S Zhang1,2, S-S Wang1, B-J Wu1, W-Y He4, N-Q Zhao5, X Gao1,2.   

Abstract

BACKGROUND: The patatin-like phospholipase 3 (PNPLA3) rs738409 gene polymorphism is an important genetic determinant of non-alcoholic fatty liver disease (NAFLD). However, the associations between liver fat and metabolic traits in rs738409 G allele carriers and the allelic influence on this association have not been fully studied. AIM: To investigate the influence of the PNPLA3 gene polymorphism on the association of liver fat with serum metabolic factors and carotid atherosclerosis.
METHODS: Liver fat was measured by quantitative ultrasound in 4300 subjects in the Shanghai Changfeng community and analysed for its association with obesity and metabolic factors in individuals with the PNPLA3 CC, CG and GG genotypes.
RESULTS: Non-alcoholic fatty liver disease occurred in 37.9% and 28.8% of the subjects with the GG and CC genotypes respectively (P < 0.001). Liver fat was significantly associated with body mass index, waist circumference, serum triglycerides, high-density lipoprotein cholesterol, fasting blood glucose and insulin in the PNPLA3 rs738409 G allele carriers (P < 0.001). Compared with the CC homozygotes, the GG homozygotes presented higher liver fat and liver fibrosis scores despite their better metabolic status (comparison of regression line slopes, P < 0.05). An increase in liver fat was accompanied by a significant increase in the average and maximum carotid intima-media thickness in subjects with the PNPLA3 CC genotype but not in those with the GG genotype.
CONCLUSIONS: PNPLA3 rs738409 G allele carriers were found to be more susceptible to the metabolic-related hepatic steatosis, and developed NAFLD and liver fibrosis despite presenting relatively better metabolic statuses and lower risks for carotid atherosclerosis.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26765961     DOI: 10.1111/apt.13521

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  18 in total

1.  The PNPLA3 rs738409 C>G variant interacts with changes in body weight over time to aggravate liver steatosis, but reduces the risk of incident type 2 diabetes.

Authors:  Ming-Feng Xia; Huan-Dong Lin; Ling-Yan Chen; Li Wu; Hui Ma; Qian Li; Qiqige Aleteng; Yu Hu; Wan-Yuan He; Jian Gao; Hua Bian; Xiao-Ying Li; Xin Gao
Journal:  Diabetologia       Date:  2019-01-23       Impact factor: 10.122

Review 2.  Metabolic aspects of adult patients with nonalcoholic fatty liver disease.

Authors:  Ludovico Abenavoli; Natasa Milic; Laura Di Renzo; Tomislav Preveden; Milica Medić-Stojanoska; Antonino De Lorenzo
Journal:  World J Gastroenterol       Date:  2016-08-21       Impact factor: 5.742

3.  PNPLA3 as a Genetic Determinant of Risk for and Severity of Non-alcoholic Fatty Liver Disease Spectrum.

Authors:  Habeeb Salameh; Muhannad Al Hanayneh; Maen Masadeh; Mohammed Naseemuddin; Tasnia Matin; Angelika Erwin; Ashwani K Singal
Journal:  J Clin Transl Hepatol       Date:  2016-07-08

Review 4.  Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).

Authors:  Ali Saeed; Robin P F Dullaart; Tim C M A Schreuder; Hans Blokzijl; Klaas Nico Faber
Journal:  Nutrients       Date:  2017-12-29       Impact factor: 5.717

5.  PNPLA3 I148M is involved in the variability in anti-NAFLD response to exenatide.

Authors:  Yunzhi Chen; Xuemei Yan; Xiao Xu; Shuhua Yuan; Fen Xu; Hua Liang
Journal:  Endocrine       Date:  2020-08-30       Impact factor: 3.633

6.  Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease.

Authors:  Anna Ludovica Fracanzani; Giuseppina Pisano; Dario Consonni; Silvia Tiraboschi; Andrea Baragetti; Cristina Bertelli; Giuseppe Danilo Norata; Paola Dongiovanni; Luca Valenti; Liliana Grigore; Tatiana Tonella; Alberico Catapano; Silvia Fargion
Journal:  PLoS One       Date:  2016-09-14       Impact factor: 3.240

7.  Vitamin D Levels Are Inversely Associated with Liver Fat Content and Risk of Non-Alcoholic Fatty Liver Disease in a Chinese Middle-Aged and Elderly Population: The Shanghai Changfeng Study.

Authors:  Dan Wang; Huandong Lin; Mingfeng Xia; Qiqige Aleteng; Xiaoming Li; Hui Ma; Baishen Pan; Jian Gao; Xin Gao
Journal:  PLoS One       Date:  2016-06-10       Impact factor: 3.240

8.  Influence of Ethnicity on the Accuracy of Non-Invasive Scores Predicting Non-Alcoholic Fatty Liver Disease.

Authors:  Ming-Feng Xia; Hannele Yki-Järvinen; Hua Bian; Huan-Dong Lin; Hong-Mei Yan; Xin-Xia Chang; You Zhou; Xin Gao
Journal:  PLoS One       Date:  2016-08-31       Impact factor: 3.240

Review 9.  Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era.

Authors:  Heather L Stevenson; Netanya S Utay
Journal:  Trop Dis Travel Med Vaccines       Date:  2016-09-27

10.  Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease: a systematic review and meta-analysis.

Authors:  Nader Salari; Niloufar Darvishi; Kamran Mansouri; Hooman Ghasemi; Melika Hosseinian-Far; Fateme Darvishi; Masoud Mohammadi
Journal:  BMC Endocr Disord       Date:  2021-06-19       Impact factor: 2.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.